Skip to main content
. Author manuscript; available in PMC: 2014 Aug 28.
Published in final edited form as: Cancer Cell. 2013 Oct 14;24(4):401–402. doi: 10.1016/j.ccr.2013.09.016

Figure 1. Therapeutic Targeting of Canonical NF-κB Pathway in MLL-Fusion Leukemia.

Figure 1

Inhibition of IKK/NF-κB signaling results in loss of epigenetic marks on HOXA9 and MEIS1 promoters, which ultimately induces cell-cycle arrest, apoptosis, and differentiation in MLL fusion leukemia cells. me3, trimethylation; me2, dimethylation. The figure is modeled on the online graphical abstract in Kuo et al. (2013), with some modifications.